Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYRWF Ayr Wellness	$0.04 -14.2%	$0.14	$0.00 ▼ $2.60	$5.24M	1.71	2.43 million shs	2.28 million shs
CARM Carisma Therapeutics	$0.29 +5.0%	$0.40	$0.14 ▼ $1.27	$11.66M	1.79	418,261 shs	265,066 shs
CSCI COSCIENS Biopharma	$3.50 -1.7%	$3.66	$1.96 ▼ $6.58	$11.20M	0.91	4,814 shs	1,491 shs
GOVX GeoVax Labs	$0.74 +5.9%	$0.81	$0.43 ▼ $11.18	$11.13M	3.27	1.31 million shs	1.18 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYRWF Ayr Wellness	-11.64%	+452.86%	-74.20%	-85.78%	-97.71%
CARM Carisma Therapeutics	+4.64%	-4.00%	-35.00%	+64.24%	-70.99%
CSCI COSCIENS Biopharma	-1.69%	-7.16%	-3.31%	+4.79%	+349,999,900.00%
GOVX GeoVax Labs	+5.87%	+11.99%	+8.01%	-18.47%	-70.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYRWF Ayr Wellness	2.7482 of 5 stars	3.3	4.0	0.0	0.0	2.7	0.0	1.3
CARM Carisma Therapeutics	2.9605 of 5 stars	3.4	5.0	0.0	0.0	2.6	0.8	0.6
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	2.6076 of 5 stars	3.5	4.0	0.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYRWF Ayr Wellness	2.50	Moderate Buy	$3.00	7,651.94% Upside
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	557.00% Upside
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
GOVX GeoVax Labs	3.00	Buy	$8.88	1,099.32% Upside

Current Analyst Ratings Breakdown

Latest AYRWF, CARM, CSCI, and GOVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
8/7/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/29/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/17/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYRWF Ayr Wellness	$463.63M	0.01	N/A	N/A	$3.14 per share	0.01
CARM Carisma Therapeutics	$10.77M	1.14	N/A	N/A	($1.10) per share	-0.27
CSCI COSCIENS Biopharma	$9.59M	1.15	N/A	N/A	$3.49 per share	1.00
GOVX GeoVax Labs	$3.95M	2.98	N/A	N/A	$0.18 per share	4.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYRWF Ayr Wellness	-$359.31M	-$3.26	N/A	N/A	N/A	-77.50%	-31.73%	-11.73%	N/A
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-211.28%	8/14/2025 (Estimated)
CSCI COSCIENS Biopharma	-$15.31M	-$5.80	N/A	∞	N/A	-194.50%	-101.01%	-43.90%	N/A
GOVX GeoVax Labs	-$24.99M	-$2.01	N/A	N/A	N/A	-403.88%	-408.80%	-279.89%	N/A

Latest AYRWF, CARM, CSCI, and GOVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/28/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	-$0.35	+$0.06	-$0.35	$0.37 million	$0.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYRWF Ayr Wellness	N/A	N/A	N/A	N/A	N/A
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYRWF Ayr Wellness	1.10	1.60	0.57
CARM Carisma Therapeutics	N/A	0.48	0.48
CSCI COSCIENS Biopharma	N/A	2.88	2.54
GOVX GeoVax Labs	N/A	2.03	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYRWF Ayr Wellness	0.91%
CARM Carisma Therapeutics	44.27%
CSCI COSCIENS Biopharma	0.73%
GOVX GeoVax Labs	6.09%

Insider Ownership

Company	Insider Ownership
AYRWF Ayr Wellness	8.10%
CARM Carisma Therapeutics	6.90%
CSCI COSCIENS Biopharma	0.10%
GOVX GeoVax Labs	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYRWF Ayr Wellness	2,440	116.19 million	106.77 million	Not Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
GOVX GeoVax Labs	10	15.93 million	15.73 million	Not Optionable

AYRWF, CARM, CSCI, and GOVX Headlines

Recent News About These Companies

GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation

July 29, 2025 | finance.yahoo.com

GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

July 28, 2025 | seekingalpha.com

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine

July 21, 2025 | finance.yahoo.com

GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand

July 16, 2025 | finance.yahoo.com

GeoVax Labs, Inc. (GOVX) - Yahoo Finance

July 11, 2025 | finance.yahoo.com

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

July 3, 2025 | finance.yahoo.com

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives

July 2, 2025 | finance.yahoo.com

GOVX - Geovax Labs Inc Dividends - Morningstar

July 2, 2025 | morningstar.comM

EQS-News: GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering

July 1, 2025 | finanzen.atF

GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering

July 1, 2025 | finance.yahoo.com

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection - Nasdaq

June 27, 2025 | nasdaq.com

GeoVax Comments on FDA Approval of Keytruda (R) in Head and Neck Cancer, Underscoring Potential for Gedeptin (R) Combination Therapy - Nasdaq

June 26, 2025 | nasdaq.com

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection

June 25, 2025 | theglobeandmail.com

EQS-News: GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

June 24, 2025 | finanzen.atF

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

June 24, 2025 | finance.yahoo.com

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting

June 17, 2025 | finance.yahoo.com

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

June 16, 2025 | finance.yahoo.com

GeoVax to Participate in BIO International Convention 2025

June 12, 2025 | finance.yahoo.com

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

June 11, 2025 | finance.yahoo.com

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

June 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYRWF, CARM, CSCI, and GOVX Company Descriptions

Ayr Wellness OTCMKTS:AYRWF

$0.04 -0.01 (-14.19%)

As of 08/13/2025 03:55 PM Eastern

Ayr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.

Carisma Therapeutics NASDAQ:CARM

$0.29 +0.01 (+5.02%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$0.29 +0.00 (+0.34%)

As of 08/13/2025 07:13 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

COSCIENS Biopharma NASDAQ:CSCI

$3.50 -0.06 (-1.69%)

Closing price 08/13/2025 03:57 PM Eastern

Extended Trading

$3.52 +0.02 (+0.43%)

As of 08/13/2025 06:02 PM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

GeoVax Labs NASDAQ:GOVX

$0.74 +0.04 (+5.87%)

As of 08/13/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time